Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

11.93
+0.05000.42%
Pre-market: 12.330.4025+3.37%05:34 EDT
Volume:2.70M
Turnover:31.91M
Market Cap:1.79B
PE:-2.66
High:12.12
Open:11.83
Low:11.46
Close:11.88
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:1.33
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:146.82
PE(LYR):-1.74

Loading ...

Biohaven (BHVN), What Is Behind The Fresh Attention?

Simply Wall St.
·
15 hours ago

Biohaven enters strategic licensing, collaboration pact with Ono Pharmaceutical

TIPRANKS
·
Yesterday

Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia

MT Newswires Live
·
Yesterday

Biohaven Licenses MoDE IgG Degrader Portfolio to Ono Pharma in Japan, South Korea, Taiwan, ASEAN for up to USD 100 Million

Reuters
·
Yesterday

Ono Pharmaceutical Co., Ltd.: Will Pay Biohaven $80 Mln as an Upfront Payment and $20 Mln as a Milestone Achievement Payment, and Royalties of Approximately 20% on Net Sales

THOMSON REUTERS
·
Yesterday

Ono Pharmaceutical Co., Ltd.: Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize Igg Degraders in Japan, South Korea, Taiwan, and Asean

THOMSON REUTERS
·
Yesterday

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular Igg Degraders in Japan and Select Asian Regions, Lead Candidate Bhv-1300 in Phase 3 for Graves' Disease

THOMSON REUTERS
·
Yesterday

Biohaven - to Receive up to $100 Mln Payments and 20% Royalties from Ono

THOMSON REUTERS
·
Yesterday

Biohaven - Ono Obtains Exclusive License for Biohaven's Igg Degraders in Japan, South Korea, Taiwan, Asean

THOMSON REUTERS
·
Yesterday

Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

MT Newswires Live
·
Sep 18

Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.

Dow Jones
·
Sep 18

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Dow Jones
·
Sep 11

Biohaven Price Target Maintained with a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 11

Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright

TIPRANKS
·
Sep 11

Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James

TIPRANKS
·
Sep 10

Biohaven falls -15.3%

TIPRANKS
·
Sep 10

U.S. Stocks on the MOVE-Lovesac, Hagerty, Biohaven

Reuters
·
Sep 10

Biohaven Drops as US FDA Seeks More BHV-7000 Safety Data

Reuters
·
Sep 10

Top Premarket Decliners

MT Newswires Live
·
Sep 10

Biohaven Shares Down 9.1% Premarket After US FDA Places Partial Clinical Hold on Co's Epilepsy Drug Trial

THOMSON REUTERS
·
Sep 10